中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2014, Vol. 49 Issue (9) :759-763    DOI: 10.11669/cpj.2014.09.014
�� �� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
IFN-�ú�IL-10��Ϊҩ���˻�������ָ��Ŀ����Կ���
��ΰ��1a,֣÷��1b,����1a,����1a,���M1b,��־��2*
1.�׶�ҽ�ƴ�ѧ���������ؿ�ҽԺ,�����н�˲��ز������о���, a.ҩ���о���; b.ҩ����,����101149; 2.�׶�ҽ�ƴ�ѧ����������̳ҽԺҩ����ѧ��, ���� 100050
ZHAO Wei-jie1a,ZHENG Mei-qin1b,WANG Bin1a,FU Lei1a,LI Pei1b,ZHAO Zhi-gang2*
1.Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, a. Pharceutical Department; b. Departmant of Pharmacy, Beijing 101149, China;2. Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China

Download: PDF (744KB)   HTML (1KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� ̽��ϸ�������Ƿ������Ϊһ��ָ������ҩ���С����ģ�͵���Ч������ 75ֻBALB/cС������Ⱦ����С����ģ��,��Ϊ13��,ҩ������2���Ժ�,ȡѪ����ȫ�λ��(CFU)����;ELISA�����Ѫ���еĦ�-������(IFN-��)�Ͱ׽���10(IL-10)��Ũ��;��ȫ�λ��������Ϊҩ���С���˻��Եı�׼,����Ѫ�еĦ�-�����غͰ׽���10�ĺ��������ߵı�ֵ��С�����ȫ�λ��������Բ��������Իع顣��� ��ȫ�λ������:��������ɳ��(Lfx)�Ͷ԰���ˮ����(PAS)������,�������������հ׶�������Ⱦ���ͳ��ѧ����;�������������Զ�����(����ƽ+������+�������,RHZ)��Ⱦ���ͳ��ѧ���졣�� ��-������:��������ɳ�ǡ��԰���ˮ����������ĸ���������հ׶��������ͳ��ѧ����;�������������Զ��������û��ͳ��ѧ���졣�۰׽���10:����������հ׶����顢��������֮���û��ͳ��ѧ���졣�ܦ�-������/�׽���10:�ȷ�������������+�������̰���������+�ȷ�������������+���׿��ǡ�����ƽ+������+�����������հ׶����������ͳ��ѧ����,��������֮���û��ͳ��ѧ���졣�ݦ�-�����ء��׽���10����-������/�׽���10��ȫ�λ���������,ȷ������r2�ֱ�Ϊ0.688��0.237��0.582������ ����Ѫ�Ц�-�����صĺ������������ж����Ʒ����Ƿ���Ч,����������Ϊ����������Ԥ�����ڽ�˾���������
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
���a
֣÷��b
����a
����a
���Mb
��־��*
�ؼ����� ���   �������   ��-������   �׽���-10     
Abstract�� OBJECTIVE To study the probability of IFN-�� and IL-10 being surrogate markers for evaluating the anti-TB activity of drugs. METHODS 75 BALB/c mice infected with H37Rv using a Glas-col inhalation exposure system, were randomized into 13 groups. After 2 months of therapy, the numbers of CFU in the lungs and the levels of IFN-�� and IL-10 in blood were determined. The relevance of IFN-��, IL-10 concentrations, the ratio of IFN-��/IL-10 and CFU were evaluated respectively. RESULTS ��CFU enumeration: the CFU of treatment groups except Lfx and PAS were significantly different from that of negative control group; the CFU of every treatment groups were significantly different from that of positive group. ��Levels of IFN-��: the levels of IFN-�� in peripheral blood of treatment groups except Lfx and PAS were significantly different from that of negative control group; the IFN-�� of every treatment groups were significantly different from that of positive group.��IL-10:There were differences exiting neither between treatment groups and negative group nor between any two treatment groups. ��IFN-��/IL-10: significantly differences were displayed between CLF, LZD+Pto, LZD+CLF, LZD+Am, HRZ and negative group respectively, while no significantly differences showed between any pair of treatment groups. ��positive corrections were displayed between IFN-��, IL-10, IFN-��/IL-10 and CFU, certainty factor(r2) were 0.688,0.237,0.582. CONCLUSION The levels of IFN-�� may be used to evaluate the anti-TB activity of drugs and may not be the surrogate markers to predict the CFU in vivo.
Keywords�� tuberculosis,   colony-forming units,   interferon gamma,   interleukin-10     
�ո�����: 2013-12-11;
��������:ʮ���塰�ش���ҩ���¡��Ƽ��ش�ר��(2012ZX09303002)
ͨѶ���� ��־��,��,��ʿ,����ҩʦ,˶ʿ����ʦ �о�����:ҽԺҩѧ������ٴ�ҩѧ Tel:(010)67098036 E-mail:1022zzg@sina.com   
���߼��: ��ΰ��,Ů,˶ʿ�о��� �о�����:�����ҩҩЧѧ��ҩ������ѧ
���ñ���:   
��ΰ��a, ֣÷��b, ����a�� .IFN-�ú�IL-10��Ϊҩ���˻�������ָ��Ŀ����Կ���[J]  �й�ҩѧ��־, 2014,V49(9): 759-763
ZHAO Wei-Jie-a, ZHENG Mei-Qin-b, WANG Bin-a etc .The Feasibility of IFN-�� and IL-10 as Surrogate Markers to Evaluating the Activity of Drugs Against Mycobacterium Tuberculosis[J]  Chinese Pharmaceutical Journal, 2014,V49(9): 759-763
��
[1] KOBASHI Y, MOURI K, YAGI S,et al. Transitional changes in T-cell responses to mycobacterium tuberculosis-specific antigens during treatment. J Infect, 2009,58(3):197-204. [2] BERTHOLET S, HORNE D J, LAUGHLIN E M,et al. Effect of chemotherapy on whole-blood cytokine responses to mycobacterium tuberculosis antigens in a small cohort of patients with pulmonary tuberculosis. Clin Vaccine Immunol, 2011,18(8):1378-1386.[3] CUI H Y,ZHANG Q,LI B,et al. The change of Th1/Th2 and pro-inflammatory cytokines in tuberculosis meningitis patients. Clin J Clinician(Electronic Edition)(�л��ٴ�ҽʦ��־,���Ӱ�),2012,6(14):4109-4111.[4] HUSSAIN R, TALAT N, SHAHID F,et al. Longitudinal tracking of cytokines after acute exposure to tuberculosis: Association of distinct cytokine patterns with protection and disease development. Clin Vaccine Immunol, 2007,14(12): 1578-1586.[5] SKOLIMOWSKA K H, RANGAKA M X, MEINTJES G,et al. Altered ratio of IFN-��/IL-10 in patients with drug resistant mycobacterium tuberculosis and HIV-tuberculosis immune reconstitution inflammatory syndrome. PLoS One, 2012,7(10):46481.[6] JAMIL B, AHAHID F, HASAN Z,et al. Interfeferon gamma/IL-10 ratio defines the disease severity in pulmonary and extra pulmonary tuberculosis.. Tuberculosis(Edinb), 2007,87(4):279-287.[7] MCDYER J F, HACKLEY M N, WALSH T E,et al. Patients with multidrug-resistant tuberculosis with low CD4+ T cell counts have impaired Th1 responses. J Immunol, 1997,158(1): 492-500.[8] VEKEMANS J, LIENHARDT C, SILLAH J S, et al. Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in the Gambia. Infect Immun, 2001,69(10):6554-6557.[9] WU-HSIEH B A, CHEN C K, CHANG J H,et al. Long-lived immune response to early secretary antigenic target 6 in individuals who had recovered from tuberculosis. Clin Infect Dis, 2001,33(8):1336-1340. [10]COOPER A M. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol,2009,27:393-422. [11]CAVALCANT Y V, BRELAZ M C, NEVES J K,et al. Role of TNF-Alpha, IFN-Gamma, and IL-10 in the development of pulmonary tuberculosis. Pulm Med,2012:745483. [12]COX H, FORD N. Linezolid for the treatment of complicated drug-resistant tuberculosis: A systematic review and meta-analysis. Int J Tuberc Lung Dis,2012,16(4):447-454. [13]REDFORD P S, BOONSTRA A, READ S,et al. Enhanced protection to mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur J Immunol, 2010,40(8):2200-2210. [14]BOUSSIOTIS V A, TSAI E Y, YUNIS E J,et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest, 2000,105(9):1317-1325.
[1] ���н� Ӧ��÷ ���� ���� �ᄚ��.èצ������������ĺ����ⶨ�о�[J]. �й�ҩѧ��־, 2012,47(2): 101-103
[2] κ�� ���� ������ �ܳɺ� �����.1��2��3-�����໯������ҽҩ������о��½�չ[J]. �й�ҩѧ��־, 2011,46(7): 481-484
[3] ������ ����� ������ ����΢.��յ���ضԿ����ҩ��С������˵ı������ü������о�[J]. �й�ҩѧ��־, 2011,46(16): 1242-1244
[4] ��ƽ�� ��ά ����� ����ƽ.���Ƽ�����4�ֿ����ҩ����Caco-2ϸ����P-gp�໥�����о�[J]. �й�ҩѧ��־, 2011,46(1): 48-53
[5] ������;�����;��ͦ;����;��С��.�����������MRL/lprС��CD4+Tϸ����ֳ��IFN-�á�IL-4���ڵĵ�������[J]. �й�ҩѧ��־, 2009,44(11): 836-841
[6] ʱ�;����;����;����;�յ�;����;��Ӣ��;������.����ɢ�����в�����ȾС��ģ�ͷ���֯����������IFN-�� mRNA����Ӱ��[J]. �й�ҩѧ��־, 2008,43(19): 1475-1478
[7] ������;������;�ſ�ƽ;������;������.ɳԷ�ӻ�ͪ��CCl4�������ά�����ü���IFN-��,TGF-��1��Ӱ��[J]. �й�ҩѧ��־, 2004,40(12): 910-912
[8] л��ƽ �־� ������ ����� ����ǫ ���麣.7���߶�С�Ķ��ٴ������ͣ��ࣩҩ��˷�֦�˾�����������о�[J]. �й�ҩѧ��־, 2003,38(05): 384-385
[9] ������;.����ƽ�ڷǽ�˸�Ⱦ�����е�Ӧ�����[J]. �й�ҩѧ��־, 2002,22(09): 554-554
[10] ������;�ܽ���;.����ν�˻���ǿ�������ڸι��ܸı����[J]. �й�ҩѧ��־, 2002,22(08): 482-483
[11] ������;���Ľ�;����ҫ;.����������������֢�ν����Ч�۲�[J]. �й�ҩѧ��־, 2002,22(04): 231-232
[12] ��ΰ��;����ɽ;�����;����;½��;.����˹̶��������ϼ�����������������ö��о�[J]. �й�ҩѧ��־, 2001,36(08): 544-547
[13] л��ƽ;���麣.��˸˾��Ŀ��ǡ��������ѽ���[J]. �й�ҩѧ��־, 2001,36(04): 225-226
[14] ��ε;��˺�;½ά��;�����;��Ρ;���Խ�;���֥;����.�׻���������ɳ���ڷν�˻������ڵ�ҩ������ѧ�о�[J]. �й�ҩѧ��־, 2001,36(02): 113-114
[15] ����Ӣ.���������ڿ���������еı�������[J]. �й�ҩѧ��־, 2001,36(02): 129-130
Copyright 2010 by �й�ҩѧ��־